Back to top
more

Redhill Biopharma (RDHL)

(Delayed Data from NSDQ)

$0.46 USD

0.46
246,006

+0.01 (1.28%)

Updated May 9, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for RDHL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Redhill Biopharma Ltd. [RDHL]

Reports for Purchase

Showing records 161 - 180 ( 228 total )

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 161

02/16/2016

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 162

02/12/2016

Company Report

Pages: 6

Meetings with Management

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 163

12/06/2015

Company Report

Pages: 4

Catalyst Calendar Active in 2016

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 164

11/10/2015

Daily Note

Pages: 5

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 165

11/10/2015

Company Report

Pages: 7

With EU Rizaport Approved, Focus Turns to GI Portfolio; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 166

11/09/2015

Company Report

Pages: 7

3Q15 Recap - Focusing on 2016 Catalysts

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 167

10/27/2015

Company Report

Pages: 13

Pipeline Update - Focus on The "Big 4"

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 50.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 168

09/15/2015

Company Report

Pages: 9

Clinical Progress and First Regulatory Success; New $33 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 169

08/03/2015

Company Report

Pages: 6

Clinical Programs Progressing on Schedule; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 170

07/30/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 171

07/29/2015

Company Report

Pages: 7

2Q15 Update - RHB-105 and Bekinda the Near-Term Focus

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 172

07/28/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 173

07/27/2015

Company Report

Pages: 4

RHB-106 Program Appears On Track

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 174

06/17/2015

Company Report

Pages: 6

EU Expansion Doubles RHB-104 Potential; New $32 Price Target; Reiterate Buy

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 175

06/16/2015

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 176

06/15/2015

Company Report

Pages: 6

RHB-105 Data Positive; PT to $30

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 177

06/15/2015

Daily Note

Pages: 4

RHB-105 Crosses Initial Hurdle; Reiterate Buy

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 178

06/10/2015

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 179

06/10/2015

Company Report

Pages: 14

RHB-105 Data Could Be Upside Catalyst

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 50.00

Research Provided by a Third Party

Company: Redhill Biopharma Ltd.

Industry: Medical - Drugs

Record: 180

06/04/2015

Daily Note

Pages: 4

RHB-105 Top-line Phase 3 Data in Two Weeks; Reiterate Buy

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party